IMR Press / EJGO / Volume 39 / Issue 4 / DOI: 10.12892/ejgo3824.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report
Complete response after docetaxel+pertuzumab+trastuzumab chemotherapy for multimetastatic positive Her-2 breast cancer
Show Less
1 Medical Oncology Unit, Institut de Cancérologie du Gard, Nîmes, France
Eur. J. Gynaecol. Oncol. 2018, 39(4), 662–664;
Published: 10 August 2018

Human epidermal growth factor receptor 2 (Her-2)-positive breast cancer has been for a long time an aggressive with poor prognosis disease. However, thanks to targeted therapies, prolonged survival is possible, even in metastatic patients. Nevertheless, while the prognosis has improved, metastatic disease is still not curable. The authors report the original case of a 73-year-old Caucasian woman who presented with a T1a hormonal receptors and Her-2 positive multimetastatic (liver, bones, pleural, adrenal gland, and nodes). The patient began chemotherapy with docetaxel + pertuzumab + trastuzumab regimen with good tolerance, and no grade 3 or more adverse effect. Ca 15-3 level before treatment was high at 729 ng/ml and carcinoembryonic antigen (CEA) was at 1.2 ng/ml. After six cycles of chemotherapy, tomography positron emission scan showed metabolic complete response. Ca 15-3 level decreased to 35 ng/ml and CEA at 0.9 ng/ml. The patient is continuing pertuzumab + trastuzumab. Docetaxel associated to pertuzumab and trastuzumab in metastatic Her2-positive breast cancer is effective and can lead to complete response.
Breast cancer
Her-2 positive
Back to top